Background:

Few epidemiologic studies have investigated trace element exposure and skin cancer risk.

Methods:

Toenail levels of mercury, selenium, chromium, iron, and zinc were measured from 6,708 women in the Nurses' Health Study (1984–2012) and 3,730 men in the Health Professionals Follow-up Study (1986–2012) with data from prior nested case–control studies. Participants were free of skin cancer at toenail collection and followed for incident basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Cox proportional hazards models were used to compute hazard ratios (HR) and 95% confidence intervals (CI) of skin cancer associated with the elements in each study. We calculated pooled multivariable HRs using a fixed-effects model. During 26 to 28 years of follow-up, 2,433 BCC, 334 SCC, and 130 melanoma cases were documented.

Results:

Higher toenail mercury levels were associated with risk of BCC [pooled HR for top vs. bottom quintiles = 1.34 (95% CI, 1.18–1.52), Ptrend < 0.0001]. Similar direct associations were found with risks of SCC [pooled HR for top vs. bottom quartiles = 1.41 (95% CI, 1.03–1.94), Ptrend = 0.04] and melanoma [pooled HR for top vs. bottom quartiles = 1.88 (95% CI, 1.12–3.16), Ptrend = 0.02]. Chromium was positively associated with BCC in women only. No associations were found between other metals and skin cancer risk.

Conclusions:

Our prospective data found that increased toenail mercury concentrations were associated with increased skin cancer risk.

Impact:

If our novel findings are confirmed, mercury may play a role in skin carcinogenesis.

Nonmelanoma skin cancers (NMSC) are the most common malignancy in the United States. Basal cell carcinoma (BCC) comprises 80% of all NMSC, and squamous cell carcinoma (SCC) largely comprises the remaining 20% (1–3). Melanoma, although not as common as NMSC, is the most lethal form of all skin cancers and comprises the majority of skin cancer-related deaths (4). The incidence of BCC, SCC, and melanoma in the United States is on the rise and represents substantial morbidity with significant social and economic burden (3–8). Growing evidence supports the role of environmental and lifestyle factors, beyond ultraviolet radiation (UVR; refs. 3, 4, 9–12), in the development of skin cancer, including exposure to heavy metals such as arsenic (As; ref. 13).

Exposure to some of these metals, such as chromium (Cr), is considered a risk factor for numerous cancers and have been classified as a carcinogen by the International Agency for Research on Cancer (IARC; ref. 14). Exposure to trace elements, including Cr, iron (Fe), mercury (Hg), selenium (Se), and zinc (Zn), has been hypothesized to play a role in both carcinogenesis of the skin and prevention of skin cancer, but evidence is limited (15–22). A recent review examining published epidemiologic literature about trace element exposure and risk of skin cancer concluded that too little data existed to draw any conclusions about exposure to Cr, Fe, and Zn and risk of skin cancer (22). Although Se was hypothesized to lower skin cancer risk, the review suggested increased risk with NMSC. No epidemiologic studies exist on exposure to Hg and skin cancer risk (22).

To investigate the potential association between toenail levels of Cr, Fe, Hg, Se, and Zn and risk of skin cancer, we conducted a prospective study based on subsets of participants with existing toenail metal levels in two large US cohorts.

Study population

The study population comprises a subset of participants from the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS). In 1976, NHS enrolled 121,700 female US registered nurses ages 30–55 years. In 1986, HPFS enrolled 51,529 male US health professionals (dentists, veterinarians, pharmacists, optometrists, osteopathic physicians, and podiatrists) ages 40–75 years. Both cohorts were followed with similar biennial questionnaires about medical history, lifestyle, and disease incidence. Follow-up rates generally exceed 90% in both cohorts. The study was approved by the human subject committees of Brigham and Women's Hospital and Harvard School of Public Health. Details of the two cohorts and skin cancer–related findings have been described elsewhere (23, 24).

Toenail clippings were provided by 33,737 (66% of HPFS) participants in 1987 and by 62,865 (52% of NHS) participants in 1982 to 1983. Demographics and lifestyle characteristics were similar among participants with and without toenail clippings (25). For the current analysis, we used existing data on toenail metal concentrations from nested case–control studies of incident cardiovascular disease (CVD; coronary heart disease and stroke) in both cohorts as well as additional toenail data sets of diabetes cases and controls from HPFS (25–28). We included incident CVD cases and their matched controls (matched on month of toenail sample return, age, race, and smoking status), and diabetes cases and their matched controls, with toenail metal levels. In HPFS, the CVD nested case–control studies excluded dentists due to possible high occupational Hg exposure (27). But the data set of diabetes cases and controls did not exclude dentists (28). We did not do any exclusion based on occupation in this study.

A total of 7,124 participants from NHS and 4,448 from HPFS with toenail metal concentrations and no prior history of cancer were available at toenail collection. Due to low skin cancer incidence among non-white participants (4), we excluded non-Caucasian participants. After these exclusions, 6,708 participants from NHS and 3,730 from HPFS remained in analysis. Toenail As levels were assessed only in a few hundred participants, and thus we did not assess As in the current study.

Assessment of toenail metal concentrations

Toenail concentrations of Cr, Fe, Hg, Se, and Zn were measured, while unaware of clinical data, using neutron activation analysis as previously described (25, 27, 28), at the University of Missouri Research Reactor Facility. Nail clipping samples from all toes were combined which, due to the elimination half-life of the metals, the growth rate of toenails, and the differential length of time (distance) from cuticle synthesis to time of clipping across the smallest to the largest toes, provided a time-integrated measure of metal exposure over approximately the previous year. Element determinations were performed in analytical batches between 2007 and 2011 for Se and 2009 and 2011 for Cr, Fe, Zn, and Hg. Potential laboratory drift was controlled by both standard comparison procedures for neutron activation analysis and repeated analysis of representative sample subsets. For quality control, toenail metal samples were co-analyzed with hair metal samples, which correlated well. Intra-assay coefficients of variability were 6.0% for Cr, 3.7% for Fe, 5.5% for Hg, 2.4% for Se, and 1.8% for Zn (25, 26, 29). In the NHS, Spearman correlation coefficients for the stability of toenail metals collected 6 years apart were 0.33 for Cr, 0.43 for Fe, 0.56 for Hg, 0.48 for Se, and 0.58 for Zn (P < 0.003 for all elements; ref. 30). Validation of these methods was reported for Se and Hg (30–34). Toenail Hg levels were correlated with fish intake in subsets of the cohort samples (30, 34, 35). Dentists had more than twice the level of Hg in toenails than non-dental health professionals (34), most likely due to occupational exposure.

Ascertainment of skin cancer cases

Skin cancer diagnosis was asked in biennial questionnaires mailed to NHS and HPFS cohorts starting in 1984 (NHS) and 1986 (HPFS). Participants who reported melanoma or SCC were asked for permission to review their medical and pathology reports. Only confirmed invasive cases of melanoma and SCC were used. Medical records were not obtained for self-reported BCC; however, previous validation studies have demonstrated high validity of self-reported BCC in both cohorts, with 96% of cases in women and 84% of men confirmed by pathology records (36, 37). Differences in skin cancer ascertainment between BCC and SCC may have in part accounted for a markedly greater incidence of BCC than SCC.

Covariates

We controlled for assay batch, and skin cancer risk factors including age (continuous), natural hair color (red, blonde, light brown, dark brown, black), number of moles on arms (0, 1–2, 3–5, ≥6), skin reaction to sun exposure for ≥2 hours as a child or adolescent (none/some redness, burn, painful burn/blisters), number of severe sunburns (0, 1–2, 3–5, ≥6), first-degree family history of melanoma (yes/no), history of physical examination (yes/no), and UVR exposure at residence. UVR exposure was measured as annual UV-B flux in mW/m2, and was created by combining the latitude, altitude, and cloud cover of each participant's current state of residence, collected every 2 years. Biennial questionnaires updated body mass index (BMI; <25.0, 25.0–29.9, 30.0–34.9, ≥35.0 kg/m2), recreational physical activity (quintiles), smoking status (never, past, current), alcohol consumption (none, 0.1–4.9 g/d, 5–9.9 g/d, 10–19.9 g/d and 20+ g/d), and citrus consumption (quintiles). Additionally, we determined fish consumption using intake information on canned tuna, dark-meat fish, and other fish from food frequency questionnaires. Participants were asked how often on average they consumed the specified amount of fish during the past year. Intake was reported in nine categories: ≤1 time per month, 1–3 per month, 1 per week, 2–4 per week, 5–6 per week, 1 per day, 2–3 per day, 4–5 per day, and 6+ per day. Participant's fish intake was computed as the sum of these sources.

Statistical analysis

We evaluated associations of toenail metal concentrations with incident skin cancer using Cox proportional hazards models from the time of toenail sampling until skin cancer diagnosis, death, or end of follow-up (return date of the 2012 biennial questionnaire), whichever came first. Participants from NHS were followed from 1984 to 2012 and HPFS from 1986 to 2012. Metal concentrations were evaluated as quintiles for BCC and quartiles for SCC and melanoma (due to smaller sample sizes). We created quantiles based on distribution of toenail metals in women and men separately. We conducted a multivariable analysis adjusting for skin cancer risk factors. We calculated hazard ratios (HRs) for skin cancer according to metal concentrations. Participants were assigned the median value in their category of metals for trend tests as continuous variables. In additional multivariable analyses, we adjusted for BMI, physical activity, alcohol consumption, and smoking status. We conducted separate analyses for BCC, SCC, and melanoma. We performed study-specific analyses and calculated pooled HRs using a fixed-effects model. P values for heterogeneity were calculated using Q statistics.

We conducted several sensitivity analyses on BCC that (i) additionally adjusted for fish intake in the multivariable analysis of Hg levels, (ii) mutually adjusted for all metal levels simultaneously, (iii) mutually adjusted for Hg and Cr levels, and (iv) was among controls of the original nested case–control studies. We conducted analyses for Hg levels and BCC risk stratified by skin cancer risk factors and fish intake and calculated P values for interaction by these factors. We also conducted a stratified analysis by follow-up time period. SAS software version 9.2 (SAS Institute Inc.) was used for all statistical analyses. All statistical tests were two-tailed, and alpha criterion was set at < 0.05.

The study population mean (SD) age was 54.7(±6.2) years for women and 59.7(±9.1) years for men at time of toenail collection (Table 1). Toenail metal levels were higher in men than in women. Distribution of skin cancer risk factors and other lifestyle factors was generally similar among women and men, except women had a higher proportion of smokers than men. Men were older, had higher alcohol intake, and higher proportions of childhood blistering reactions to sun and 6+ blistering sunburns.

Table 1.

Baseline characteristics of women in the NHS (1984) and men in the HPFS (1986) with toenail element levels

Study
CharacteristicWomen (n = 6,708)Men (n = 3,730)
Age, yearsa 54.7 ± 6.2 59.7 ± 9.1 
Toenail mercury, μg/g 0.31 ± 0.74 0.54 ± 1.41 
Toenail selenium, μg/g 0.79 ± 0.26 0.98 ± 0.91 
Toenail chromium, μg/g 0.86 ± 2.83 0.89 ± 1.82 
Toenail iron, μg/g 19.0 ± 139.9 21.7 ± 31.2 
Toenail zinc, μg/g 70.9 ± 43.9 84.8 ± 46.3 
Red/blonde hair, % 16.2 14.3 
Painful burn/blisters reaction as a child/adolescent, % 36.6 61.5 
Number of blistering sunburns 6+, % 6.0 33.2 
Number of moles (>3 mm) on arms 6+, % 4.9 5.9 
UV exposure at residence, mW/m2 190 ± 31 192 ± 28 
Family history of melanoma, % 2.9 1.9 
BMI, kg/m2 25.6 ± 5.0 25.3 ± 5.1 
Physical activity level, metabolic-equivalents hours/week 14.7 ± 19.6 18.4 ± 27.5 
Alcohol intake, g/d 7.5 ± 12.5 12.0 ± 17.2 
Smoker, % 33.0 10.4 
Total citrus intake, servings/day 0.9 ± 0.8 1.0 ± 1.0 
Total fish intake, servings/day 0.3 ± 0.2 0.3 ± 0.3 
Study
CharacteristicWomen (n = 6,708)Men (n = 3,730)
Age, yearsa 54.7 ± 6.2 59.7 ± 9.1 
Toenail mercury, μg/g 0.31 ± 0.74 0.54 ± 1.41 
Toenail selenium, μg/g 0.79 ± 0.26 0.98 ± 0.91 
Toenail chromium, μg/g 0.86 ± 2.83 0.89 ± 1.82 
Toenail iron, μg/g 19.0 ± 139.9 21.7 ± 31.2 
Toenail zinc, μg/g 70.9 ± 43.9 84.8 ± 46.3 
Red/blonde hair, % 16.2 14.3 
Painful burn/blisters reaction as a child/adolescent, % 36.6 61.5 
Number of blistering sunburns 6+, % 6.0 33.2 
Number of moles (>3 mm) on arms 6+, % 4.9 5.9 
UV exposure at residence, mW/m2 190 ± 31 192 ± 28 
Family history of melanoma, % 2.9 1.9 
BMI, kg/m2 25.6 ± 5.0 25.3 ± 5.1 
Physical activity level, metabolic-equivalents hours/week 14.7 ± 19.6 18.4 ± 27.5 
Alcohol intake, g/d 7.5 ± 12.5 12.0 ± 17.2 
Smoker, % 33.0 10.4 
Total citrus intake, servings/day 0.9 ± 0.8 1.0 ± 1.0 
Total fish intake, servings/day 0.3 ± 0.2 0.3 ± 0.3 

NOTE: Values are mean ± SD or percentages (categorical characteristics) and are standardized to the age distribution of the study population.

aValues are not age adjusted.

Participants with higher toenail Hg levels were more likely to consume fish, citrus, and alcohol, as well as more likely to exercise, and live in areas with greater UV exposure among both women and men (Table 2). Among men, participants with higher Hg levels were less likely to be smokers. The Spearman correlation coefficients between toenail Hg levels and fish intake were 0.34 (P < 0.0001) in women and 0.44 (P < 0.0001) in men.

Table 2.

Baseline characteristics according to quintiles of toenail mercury levels in the NHS (1984) and HPFS (1986) with toenail element levels

CharacteristicQuintiles of toenail mercury concentration
Women (n = 6,708)Q1 (n = 1,366)Q2 (n = 1,348)Q3 (n = 1,349)Q4 (n = 1,349)Q5 (n = 1,296)
Age, yearsa 54.9 ± 6.1 54.4 ± 6.3 54.7 ± 6.2 54.8 ± 6.2 54.8 ± 6.2 
Toenail mercury, μg/g 0.08 ± 0.03 0.15 ± 0.02 0.22 ± 0.02 0.32 ± 0.04 0.83 ± 1.56 
Toenail selenium, μg/g 0.80 ± 0.29 0.80 ± 0.34 0.78 ± 0.16 0.79 ± 0.18 0.80 ± 0.25 
Toenail chromium, μg/g 0.72 ± 1.78 0.79 ± 1.35 0.83 ± 1.55 0.91 ± 1.78 1.03 ± 5.21 
Toenail iron, μg/g 16.6 ± 16.5 16.6 ± 16.7 17.2 ± 24.3 18.0 ± 24.0 26.0 ± 298.5 
Toenail zinc, μg/g 69.2 ± 17.9 70.3 ± 21.5 71.4 ± 79.0 69.7 ± 18.2 73.6 ± 49.2 
Red/blonde hair, % 14.1 16.7 16.1 17.4 16.8 
Painful burn/blisters reaction as a child/adolescent, % 38.6 38.0 34.9 35.5 35.1 
Number of blistering sunburns, 6+, % 5.3 5.1 6.7 6.3 6.8 
Number of arm moles (>3 mm), 6+, % 5.6 4.7 4.3 5.0 4.9 
UV exposure at residence, mW/m2 185 ± 27 187 ± 29 190 ± 30 194 ± 33 197 ± 34 
Family history of melanoma, % 3.1 3.2 3.0 2.3 2.7 
BMI, kg/m2 26.1 ± 5.3 25.9 ± 5.1 25.3 ± 4.9 25.5 ± 4.9 25.2 ± 4.7 
Physical activity level, metabolic-equivalents hours/week 13.5 ± 19.5 13.6 ± 23.5 14.7 ± 17.8 15.3 ± 20.2 16.3 ± 17.8 
Alcohol intake, g/d 4.5 ± 10.2 5.7 ± 10.6 7.7 ± 12.8 9.5 ± 13.3 10.3 ± 14.2 
Smoker, % 32.3 33.6 33.2 33.1 32.8 
Total citrus intake, servings/day 0.8 ± 0.7 0.9 ± 0.7 0.9 ± 0.8 0.9 ± 0.8 1.0 ± 0.8 
Total fish intake, servings/day 0.2 ± 0.1 0.2 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 
CharacteristicQuintiles of toenail mercury concentration
Women (n = 6,708)Q1 (n = 1,366)Q2 (n = 1,348)Q3 (n = 1,349)Q4 (n = 1,349)Q5 (n = 1,296)
Age, yearsa 54.9 ± 6.1 54.4 ± 6.3 54.7 ± 6.2 54.8 ± 6.2 54.8 ± 6.2 
Toenail mercury, μg/g 0.08 ± 0.03 0.15 ± 0.02 0.22 ± 0.02 0.32 ± 0.04 0.83 ± 1.56 
Toenail selenium, μg/g 0.80 ± 0.29 0.80 ± 0.34 0.78 ± 0.16 0.79 ± 0.18 0.80 ± 0.25 
Toenail chromium, μg/g 0.72 ± 1.78 0.79 ± 1.35 0.83 ± 1.55 0.91 ± 1.78 1.03 ± 5.21 
Toenail iron, μg/g 16.6 ± 16.5 16.6 ± 16.7 17.2 ± 24.3 18.0 ± 24.0 26.0 ± 298.5 
Toenail zinc, μg/g 69.2 ± 17.9 70.3 ± 21.5 71.4 ± 79.0 69.7 ± 18.2 73.6 ± 49.2 
Red/blonde hair, % 14.1 16.7 16.1 17.4 16.8 
Painful burn/blisters reaction as a child/adolescent, % 38.6 38.0 34.9 35.5 35.1 
Number of blistering sunburns, 6+, % 5.3 5.1 6.7 6.3 6.8 
Number of arm moles (>3 mm), 6+, % 5.6 4.7 4.3 5.0 4.9 
UV exposure at residence, mW/m2 185 ± 27 187 ± 29 190 ± 30 194 ± 33 197 ± 34 
Family history of melanoma, % 3.1 3.2 3.0 2.3 2.7 
BMI, kg/m2 26.1 ± 5.3 25.9 ± 5.1 25.3 ± 4.9 25.5 ± 4.9 25.2 ± 4.7 
Physical activity level, metabolic-equivalents hours/week 13.5 ± 19.5 13.6 ± 23.5 14.7 ± 17.8 15.3 ± 20.2 16.3 ± 17.8 
Alcohol intake, g/d 4.5 ± 10.2 5.7 ± 10.6 7.7 ± 12.8 9.5 ± 13.3 10.3 ± 14.2 
Smoker, % 32.3 33.6 33.2 33.1 32.8 
Total citrus intake, servings/day 0.8 ± 0.7 0.9 ± 0.7 0.9 ± 0.8 0.9 ± 0.8 1.0 ± 0.8 
Total fish intake, servings/day 0.2 ± 0.1 0.2 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 
Men (n = 3,730)Q1 (n = 757)Q2 (n = 748)Q3 (n = 752)Q4 (n = 743)Q5 (n = 730)
Age, yearsa 59.2 ± 9.1 59.7 ± 9.0 59.6 ± 9.3 59.6 ± 8.9 59.0 ± 8.0 
Toenail mercury, μg/g 0.11 ± 0.04 0.21 ± 0.03 0.33 ± 0.05 0.54 ± 0.08 1.55 ± 3.07 
Toenail selenium, μg/g 0.94 ± 0.54 0.99 ± 1.17 0.99 ± 1.26 0.99 ± 0.77 1.01 ± 0.74 
Toenail chromium, μg/g 0.71 ± 1.25 0.74 ± 0.95 0.93 ± 3.04 0.95 ± 1.41 1.06 ± 1.53 
Toenail iron, μg/g 20.3 ± 32.3 19.7 ± 17.2 22.6 ± 50.6 22.3 ± 26.2 24.5 ± 42.3 
Toenail zinc, μg/g 77.9 ± 42.6 83.2 ± 58.3 84.2 ± 38.5 85.8 ± 34.5 91.9 ± 51.4 
Red/blonde hair, % 16.7 14.1 14.2 13.1 12.3 
Painful burn/blisters reaction as a child/adolescent, % 61.1 61.1 63.4 60.1 61.3 
Number of blistering sunburns 6+, % 34.4 33.0 33.4 31.9 32.1 
Number of arm moles (>3 mm) 6+, % 6.7 5.1 6.1 6.1 5.9 
UV exposure at residence, mW/m2 191 ± 26 193 ± 27 192 ± 27 193 ± 29 193 ± 31 
Family history of melanoma, % 1.8 1.9 1.5 2.3 1.3 
BMI, kg/m2 25.6 ± 5.6 25.4 ± 5.0 25.3 ± 4.7 25.1 ± 5.5 25.0 ± 4.8 
Physical activity level, metabolic-equivalent hours/week 16.8 ± 30.5 17.2 ± 26.6 18.2 ± 26.4 19.2 ± 27.8 21.0 ± 23.8 
Alcohol intake, g/d 10.9 ± 16.9 11.2 ± 17.2 12.0 ± 16.1 12.4 ± 16.1 13.2 ± 18.5 
Smoker, % 13.2 12.3 10.3 8.4 7.5 
Total citrus intake, servings/day 0.9 ± 1.0 1.0 ± 1.1 1.0 ± 1.0 1.1 ± 1.0 1.1 ± 1.1 
Total fish intake, servings/day 0.2 ± 0.2 0.2 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.5 ± 0.4 
Men (n = 3,730)Q1 (n = 757)Q2 (n = 748)Q3 (n = 752)Q4 (n = 743)Q5 (n = 730)
Age, yearsa 59.2 ± 9.1 59.7 ± 9.0 59.6 ± 9.3 59.6 ± 8.9 59.0 ± 8.0 
Toenail mercury, μg/g 0.11 ± 0.04 0.21 ± 0.03 0.33 ± 0.05 0.54 ± 0.08 1.55 ± 3.07 
Toenail selenium, μg/g 0.94 ± 0.54 0.99 ± 1.17 0.99 ± 1.26 0.99 ± 0.77 1.01 ± 0.74 
Toenail chromium, μg/g 0.71 ± 1.25 0.74 ± 0.95 0.93 ± 3.04 0.95 ± 1.41 1.06 ± 1.53 
Toenail iron, μg/g 20.3 ± 32.3 19.7 ± 17.2 22.6 ± 50.6 22.3 ± 26.2 24.5 ± 42.3 
Toenail zinc, μg/g 77.9 ± 42.6 83.2 ± 58.3 84.2 ± 38.5 85.8 ± 34.5 91.9 ± 51.4 
Red/blonde hair, % 16.7 14.1 14.2 13.1 12.3 
Painful burn/blisters reaction as a child/adolescent, % 61.1 61.1 63.4 60.1 61.3 
Number of blistering sunburns 6+, % 34.4 33.0 33.4 31.9 32.1 
Number of arm moles (>3 mm) 6+, % 6.7 5.1 6.1 6.1 5.9 
UV exposure at residence, mW/m2 191 ± 26 193 ± 27 192 ± 27 193 ± 29 193 ± 31 
Family history of melanoma, % 1.8 1.9 1.5 2.3 1.3 
BMI, kg/m2 25.6 ± 5.6 25.4 ± 5.0 25.3 ± 4.7 25.1 ± 5.5 25.0 ± 4.8 
Physical activity level, metabolic-equivalent hours/week 16.8 ± 30.5 17.2 ± 26.6 18.2 ± 26.4 19.2 ± 27.8 21.0 ± 23.8 
Alcohol intake, g/d 10.9 ± 16.9 11.2 ± 17.2 12.0 ± 16.1 12.4 ± 16.1 13.2 ± 18.5 
Smoker, % 13.2 12.3 10.3 8.4 7.5 
Total citrus intake, servings/day 0.9 ± 1.0 1.0 ± 1.1 1.0 ± 1.0 1.1 ± 1.0 1.1 ± 1.1 
Total fish intake, servings/day 0.2 ± 0.2 0.2 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.5 ± 0.4 

NOTE: Values are means ± SD (continuous characteristics) or percentages (categorical characteristics) and are standardized to the age distribution of the study population.

aValue is not age adjusted.

During 26–28 years of follow-up, 2,433 BCC (1,553 women and 880 men), 334 SCC, and 130 melanoma cases were documented. Average follow-up times for diagnosis of BCC were 14 years in NHS and 12 years in HPFS. Table 3 presents the associations between toenail element concentrations and risk of BCC. Higher toenail Hg levels were associated with increased risk of BCC; the pooled multivariable HRs for the increasing quintiles of toenail Hg levels were 1.00 (reference), 1.00 (0.88–1.15), 1.13 (0.99–1.28), 1.27 (1.11–1.44), and 1.34 (1.18–1.52; Ptrend < 0.0001). The positive association was consistent in women and men. Also, Cr was positively associated with BCC in women [top vs. bottom quintiles HR = 1.37 (95% CI, 1.17–1.60), Ptrend < 0.0001[, but not in men. No associations were observed between other elements and BCC risk. The results remained similar when we additionally adjusted for BMI, physical activity, smoking status, alcohol consumption, and citrus intake [top vs. bottom quintiles HR for Hg = 1.27 (95% CI, 1.11–1.45)]. We conducted a multivariable analysis mutually adjusting for all of the metals simultaneously. The association between Hg levels and BCC risk remained similar and still significant [top vs. bottom quintiles HR for Hg = 1.36 (95% CI, 1.19–1.57)]. Similarly, the positive association between Cr levels and BCC risk in women remained significant [top vs. bottom quintiles HR for Cr = 1.33 (95% CI, 1.13–1.55) adjusted for BMI, physical activity, smoking status, alcohol consumption, and citrus intake, and 1.32 (95% CI, 1.12–1.56) adjusted for all metals simultaneously].

Table 3.

HR and 95% CI of BCC according to toenail element exposure among women in the NHS and men in the HPFS

Quintiles of toenail element concentrationa
ElementCohortQ1Q2Q3Q4Q5Ptrend
Mercury Women (NHS)       
 Median (μg/g) 0.09 0.15 0.22 0.31 0.56  
 No. events 260 269 306 356 362  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.05 (0.89–1.25) 1.18 (1.00–1.40) 1.41 (1.20–1.66) 1.50 (1.28–1.76) <0.0001 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.03 (0.87–1.23) 1.15 (0.98–1.36) 1.37 (1.16–1.61) 1.43 (1.21–1.68) <0.0001 
 Men (HPFS)       
 Median (μg/g) 0.11 0.21 0.33 0.52 1.05  
 No. events 167 161 178 184 190  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.98 (0.79–1.22) 1.10 (0.89–1.36) 1.09 (0.88–1.34) 1.20 (0.97–1.48) 0.05 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.96 (0.77–1.20) 1.08 (0.87–1.34) 1.10 (0.89–1.37) 1.20 (0.96–1.48) 0.04 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.00 (0.88–1.15) 1.13 (0.99–1.28) 1.27 (1.11–1.44) 1.34 (1.18–1.52) <0.0001 
Selenium Women (NHS)       
 Median (μg/g) 0.63 0.71 0.77 0.83 0.95  
 No. events 292 329 310 313 309  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.06 (0.91–1.25) 0.99 (0.85–1.17) 0.99 (0.85–1.17) 1.03 (0.88–1.21) 0.98 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.89–1.22) 0.96 (0.82–1.13) 0.96 (0.81–1.12) 0.97 (0.83–1.14) 0.48 
 Men (HPFS)       
 Median (μg/g) 0.67 0.77 0.84 0.94 1.17  
 No. events 158 178 180 180 184  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.09 (0.88–1.35) 1.04 (0.84–1.29) 1.07 (0.86–1.33) 1.05 (0.85–1.30) 0.84 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.10 (0.88–1.36) 1.07 (0.86–1.33) 1.06 (0.85–1.33) 1.03 (0.82–1.30) 0.99 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.06 (0.93–1.20) 1.00 (0.88–1.13) 0.99 (0.87–1.13) 0.99 (0.87–1.13) 0.64 
Chromium Women (NHS)       
 Median (μg/g) 0.12 0.24 0.41 0.71 1.78  
 No. events 295 287 278 319 374  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.97 (0.83–1.14) 0.98 (0.83–1.15) 1.09 (0.93–1.28) 1.34 (1.15–1.56) <0.0001 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.84–1.16) 0.99 (0.84–1.16) 1.11 (0.95–1.30) 1.37 (1.17–1.60) <0.0001 
 Men (HPFS)       
 Median (μg/g) 0.13 0.28 0.47 0.81 1.85  
 No. events 175 188 168 174 175  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.97 (0.74–1.25) 0.91 (0.70–1.18) 0.90 (0.69–1.17) 1.03 (0.80–1.34) 0.62 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.00 (0.77–1.29) 0.92 (0.71–1.20) 0.92 (0.70–1.20) 1.07 (0.82–1.39) 0.48 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.03 (0.90–1.17) 0.98 (0.86–1.11) 1.08 (0.95–1.22) 1.24 (1.09–1.41) <0.0001 
Iron Women (NHS)       
 Median (μg/g) 6.22 9.23 12.55 17.75 31.71  
 No. events 320 316 279 312 326  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.00 (0.86–1.17) 0.88 (0.75–1.04) 1.01 (0.87–1.18) 1.08 (0.92–1.26) 0.15 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.01 (0.86–1.18) 0.89 (0.76–1.05) 1.02 (0.87–1.19) 1.09 (0.93–1.27) 0.15 
 Men (HPFS)       
 Median (μg/g) 6.48 10.1 14.47 21.67 41.7  
 No. events 175 174 174 193 164  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.11 (0.90–1.37) 1.10 (0.89–1.37) 1.25 (1.02–1.54) 1.04 (0.84–1.29) 0.90 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.11 (0.90–1.37) 1.12 (0.90–1.39) 1.23 (0.99–1.52) 1.03 (0.82–1.29) 0.88 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.92–1.18) 0.97 (0.85–1.10) 1.08 (0.96–1.23) 1.07 (0.94–1.21) 0.36 
Zinc Women (NHS)       
 Median (μg/g) 48.92 60.62 68.65 77.05 91.17  
 No. events 335 314 290 312 302  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.80–1.09) 0.85 (0.73–1.00) 0.95 (0.81–1.11) 0.94 (0.81–1.10) 0.55 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.81–1.10) 0.87 (0.75–1.02) 0.96 (0.82–1.12) 0.95 (0.81–1.11) 0.60 
 Men (HPFS)       
 Median (μg/g) 52.17 65.44 77.36 91.53 116.85  
 No. events 174 176 198 171 161  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.97 (0.79–1.20) 1.17 (0.96–1.44) 1.07 (0.87–1.33) 0.97 (0.78–1.21) 0.90 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.93 (0.75–1.15) 1.08 (0.87–1.35) 0.97 (0.76–1.25) 0.83 (0.64–1.09) 0.20 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.83–1.06) 0.94 (0.83–1.07) 0.96 (0.85–1.10) 0.92 (0.80–1.05) 0.22 
Quintiles of toenail element concentrationa
ElementCohortQ1Q2Q3Q4Q5Ptrend
Mercury Women (NHS)       
 Median (μg/g) 0.09 0.15 0.22 0.31 0.56  
 No. events 260 269 306 356 362  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.05 (0.89–1.25) 1.18 (1.00–1.40) 1.41 (1.20–1.66) 1.50 (1.28–1.76) <0.0001 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.03 (0.87–1.23) 1.15 (0.98–1.36) 1.37 (1.16–1.61) 1.43 (1.21–1.68) <0.0001 
 Men (HPFS)       
 Median (μg/g) 0.11 0.21 0.33 0.52 1.05  
 No. events 167 161 178 184 190  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.98 (0.79–1.22) 1.10 (0.89–1.36) 1.09 (0.88–1.34) 1.20 (0.97–1.48) 0.05 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.96 (0.77–1.20) 1.08 (0.87–1.34) 1.10 (0.89–1.37) 1.20 (0.96–1.48) 0.04 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.00 (0.88–1.15) 1.13 (0.99–1.28) 1.27 (1.11–1.44) 1.34 (1.18–1.52) <0.0001 
Selenium Women (NHS)       
 Median (μg/g) 0.63 0.71 0.77 0.83 0.95  
 No. events 292 329 310 313 309  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.06 (0.91–1.25) 0.99 (0.85–1.17) 0.99 (0.85–1.17) 1.03 (0.88–1.21) 0.98 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.89–1.22) 0.96 (0.82–1.13) 0.96 (0.81–1.12) 0.97 (0.83–1.14) 0.48 
 Men (HPFS)       
 Median (μg/g) 0.67 0.77 0.84 0.94 1.17  
 No. events 158 178 180 180 184  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.09 (0.88–1.35) 1.04 (0.84–1.29) 1.07 (0.86–1.33) 1.05 (0.85–1.30) 0.84 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.10 (0.88–1.36) 1.07 (0.86–1.33) 1.06 (0.85–1.33) 1.03 (0.82–1.30) 0.99 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.06 (0.93–1.20) 1.00 (0.88–1.13) 0.99 (0.87–1.13) 0.99 (0.87–1.13) 0.64 
Chromium Women (NHS)       
 Median (μg/g) 0.12 0.24 0.41 0.71 1.78  
 No. events 295 287 278 319 374  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.97 (0.83–1.14) 0.98 (0.83–1.15) 1.09 (0.93–1.28) 1.34 (1.15–1.56) <0.0001 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.84–1.16) 0.99 (0.84–1.16) 1.11 (0.95–1.30) 1.37 (1.17–1.60) <0.0001 
 Men (HPFS)       
 Median (μg/g) 0.13 0.28 0.47 0.81 1.85  
 No. events 175 188 168 174 175  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.97 (0.74–1.25) 0.91 (0.70–1.18) 0.90 (0.69–1.17) 1.03 (0.80–1.34) 0.62 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.00 (0.77–1.29) 0.92 (0.71–1.20) 0.92 (0.70–1.20) 1.07 (0.82–1.39) 0.48 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.03 (0.90–1.17) 0.98 (0.86–1.11) 1.08 (0.95–1.22) 1.24 (1.09–1.41) <0.0001 
Iron Women (NHS)       
 Median (μg/g) 6.22 9.23 12.55 17.75 31.71  
 No. events 320 316 279 312 326  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.00 (0.86–1.17) 0.88 (0.75–1.04) 1.01 (0.87–1.18) 1.08 (0.92–1.26) 0.15 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.01 (0.86–1.18) 0.89 (0.76–1.05) 1.02 (0.87–1.19) 1.09 (0.93–1.27) 0.15 
 Men (HPFS)       
 Median (μg/g) 6.48 10.1 14.47 21.67 41.7  
 No. events 175 174 174 193 164  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.11 (0.90–1.37) 1.10 (0.89–1.37) 1.25 (1.02–1.54) 1.04 (0.84–1.29) 0.90 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.11 (0.90–1.37) 1.12 (0.90–1.39) 1.23 (0.99–1.52) 1.03 (0.82–1.29) 0.88 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.92–1.18) 0.97 (0.85–1.10) 1.08 (0.96–1.23) 1.07 (0.94–1.21) 0.36 
Zinc Women (NHS)       
 Median (μg/g) 48.92 60.62 68.65 77.05 91.17  
 No. events 335 314 290 312 302  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.80–1.09) 0.85 (0.73–1.00) 0.95 (0.81–1.11) 0.94 (0.81–1.10) 0.55 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.81–1.10) 0.87 (0.75–1.02) 0.96 (0.82–1.12) 0.95 (0.81–1.11) 0.60 
 Men (HPFS)       
 Median (μg/g) 52.17 65.44 77.36 91.53 116.85  
 No. events 174 176 198 171 161  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.97 (0.79–1.20) 1.17 (0.96–1.44) 1.07 (0.87–1.33) 0.97 (0.78–1.21) 0.90 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.93 (0.75–1.15) 1.08 (0.87–1.35) 0.97 (0.76–1.25) 0.83 (0.64–1.09) 0.20 
 Women and men pooled       
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.83–1.06) 0.94 (0.83–1.07) 0.96 (0.85–1.10) 0.92 (0.80–1.05) 0.22 

Abbreviation: CI, confidence interval.

aMultivariable model was adjusted for assay batch, age (in years), number of severe sunburns (0, 1–2, 3–5, ≥6), number of moles (0, 1–2, 3–5, ≥6), hair color (red, blonde, light brown, dark brown, or black), family history of melanoma (yes, no), history of SCC or melanoma (yes, no), UV exposure at residence (quintiles), history of physical examination (yes, no), and sun reactions (none, burn, painful burn/blisters) in HPFS and Fitzpatrick score (I–VI) in NHS.

Because fish intake is the major source of Hg in the United States (38, 39), and correlated with Hg levels in the cohorts, we adjusted for fish intake in the analysis of Hg levels and BCC risk. The pooled multivariable HR for top versus bottom quintiles of Hg levels was slightly attenuated to 1.24 (95% CI, 1.08–1.41, Ptrend = 0.003) after adjustment of fish intake. Fish intake was similarly positively associated with BCC risk; the pooled multivariable HRs for top versus bottom quintiles of fish intake were 1.33 (95% CI, 1.17–1.52, Ptrend < 0.001). When Hg levels were adjusted for simultaneously, the HR for top versus bottom quintiles of fish was somewhat attenuated to 1.23 (95% CI, 1.07–1.42; Ptrend = 0.004). We also adjusted for omega-3 fat intake, because fish is a major source of omega-3 fat. The pooled multivariable HR for top versus bottom quintiles of Hg levels remained essentially unchanged [HR = 1.30 (95% CI, 1.14–1.49), Ptrend <0.0001] after adjustment of omega-3 fat intake.

We conducted stratified analyses of toenail Hg levels and BCC risk by fish consumption and known skin cancer risk factors including hair color, sunburns, skin reaction to sun exposure, and UV exposure at residence among women and men (Table 4). This was to explore whether Hg exposure might interact with any of the skin cancer risk factors, which may provide some biological explanations regarding how Hg could affect skin cancer. None of the P values for interaction were significant. Higher toenail levels of Hg were associated with BCC risk among those with low fish consumption [top vs. bottom quintiles HR = 1.46 (95% CI, 1.18–1.81), Ptrend < 0.0001] and with brown/black hair [top vs. bottom quintiles HR = 1.37 (95% CI, 1.18–1.59), Ptrend < 0.0001]. The associations were similar and significant by experience of severe sunburns, skin reaction to sun, and UV exposure. The results were similar in women and men (Supplementary Table S1). We also conducted a stratified analysis by follow-up time (up to 1996 vs. 1996–2012). The associations between Hg levels and BCC risk were similar by follow-up time [top vs. bottom quintiles HR = 1.43 (95% CI, 1.17–1.75) for up to 1996 and 1.27 (95% CI, 1.07–1.50) for 1996–2012]. We also conducted a sensitivity analysis among those who were controls of the original nested case–control studies; the association between Hg levels and BCC risk remained essentially unchanged [top vs bottom quintiles HR = 1.29 (95% CI, 1.07–1.55)]. Hg levels in the controls (0.51 μg/g in HPFS and 0.32 μg/g in NHS) were similar to those of non-controls (0.56 μg/g in HPFS and 0.31 μg/g in NHS).

Table 4.

Pooled multivariable-adjusted HR and 95% CI of BCC according to toenail mercury exposure by fish intake and skin cancer risk factors in NHS and HPFS

Quintiles of toenail mercury concentrationa
SubgroupsNQ1Q2Q3Q4Q5Ptrend
Fish intake 
 Low fish intake 1,011 1.00 (reference) 0.96 (0.80–1.16) 1.27 (1.05–1.53) 1.27 (1.05–1.55) 1.46 (1.18–1.81) <0.0001 
 High fish intake 1,380 1.00 (reference) 0.93 (0.75–1.16) 0.89 (0.72–1.09) 1.00 (0.82–1.23) 0.99 (0.81–1.20) 0.77 
Hair color 
 Red/blonde hair 431 1.00 (reference) 0.87 (0.63–1.21) 0.90 (0.65–1.25) 1.22 (0.89–1.69) 1.18 (0.85–1.64) 0.09 
 Other hair color 1,944 1.00 (reference) 1.06 (0.91–1.24) 1.17 (1.00–1.35) 1.28 (1.11–1.49) 1.37 (1.18–1.59) <0.0001 
Sunburns 
 Severe sunburns 1,263 1.00 (reference) 0.96 (0.79–1.16) 1.00 (0.83–1.20) 1.26 (1.05–1.51) 1.33 (1.11–1.59) 0.0003 
 No severe sunburns 945 1.00 (reference) 1.11 (0.89–1.38) 1.30 (1.05–1.60) 1.29 (1.04–1.60) 1.24 (1.00–1.54) 0.09 
Sun reaction 
 No sun reaction 1,120 1.00 (reference) 0.94 (0.76–1.16) 1.07 (0.88–1.31) 1.18 (0.97–1.44) 1.23 (1.01–1.49) 0.02 
 Burns or other reaction 1,241 1.00 (reference) 1.08 (0.90–1.31) 1.12 (0.93–1.36) 1.36 (1.14–1.64) 1.37 (1.14–1.65) 0.0007 
UV exposure at residence 
 Low UV exposure 990 1.00 (reference) 0.87 (0.70–1.07) 1.06 (0.87–1.29) 1.20 (0.98–1.46) 1.42 (1.17–1.73) <0.0001 
 High UV exposure 1,286 1.00 (reference) 1.09 (0.90–1.32) 1.12 (0.93–1.35) 1.28 (1.07–1.54) 1.23 (1.02–1.48) 0.09 
Quintiles of toenail mercury concentrationa
SubgroupsNQ1Q2Q3Q4Q5Ptrend
Fish intake 
 Low fish intake 1,011 1.00 (reference) 0.96 (0.80–1.16) 1.27 (1.05–1.53) 1.27 (1.05–1.55) 1.46 (1.18–1.81) <0.0001 
 High fish intake 1,380 1.00 (reference) 0.93 (0.75–1.16) 0.89 (0.72–1.09) 1.00 (0.82–1.23) 0.99 (0.81–1.20) 0.77 
Hair color 
 Red/blonde hair 431 1.00 (reference) 0.87 (0.63–1.21) 0.90 (0.65–1.25) 1.22 (0.89–1.69) 1.18 (0.85–1.64) 0.09 
 Other hair color 1,944 1.00 (reference) 1.06 (0.91–1.24) 1.17 (1.00–1.35) 1.28 (1.11–1.49) 1.37 (1.18–1.59) <0.0001 
Sunburns 
 Severe sunburns 1,263 1.00 (reference) 0.96 (0.79–1.16) 1.00 (0.83–1.20) 1.26 (1.05–1.51) 1.33 (1.11–1.59) 0.0003 
 No severe sunburns 945 1.00 (reference) 1.11 (0.89–1.38) 1.30 (1.05–1.60) 1.29 (1.04–1.60) 1.24 (1.00–1.54) 0.09 
Sun reaction 
 No sun reaction 1,120 1.00 (reference) 0.94 (0.76–1.16) 1.07 (0.88–1.31) 1.18 (0.97–1.44) 1.23 (1.01–1.49) 0.02 
 Burns or other reaction 1,241 1.00 (reference) 1.08 (0.90–1.31) 1.12 (0.93–1.36) 1.36 (1.14–1.64) 1.37 (1.14–1.65) 0.0007 
UV exposure at residence 
 Low UV exposure 990 1.00 (reference) 0.87 (0.70–1.07) 1.06 (0.87–1.29) 1.20 (0.98–1.46) 1.42 (1.17–1.73) <0.0001 
 High UV exposure 1,286 1.00 (reference) 1.09 (0.90–1.32) 1.12 (0.93–1.35) 1.28 (1.07–1.54) 1.23 (1.02–1.48) 0.09 

aMultivariable model was adjusted for assay batch, age (in years), number of severe sunburns (0, 1–2, 3–5, ≥6), number of moles (0, 1–2, 3–5, ≥6), hair color (red, blonde, light brown, dark brown, or black), family history of melanoma (yes, no), history of SCC or melanoma (yes, no), UV exposure at residence (quintiles), history of physical examination (yes, no), and sun reactions (none, burn, painful burn/blisters) in HPFS and Fitzpatrick score (I–VI) in NHS.

We found similar direct associations between toenail Hg levels and risks of SCC [Table 5; pooled multivariable HR for top vs. bottom quartiles = 1.41 (95% CI, 1.03–1.94), Ptrend = 0.04] and melanoma [Table 6; pooled multivariable HR for top versus bottom quartiles = 1.88 (95% CI, 1.12–3.16), Ptrend = 0.02]. Fish intake had a nonsignificant, positive direction of association with SCC [pooled multivariable HR for top vs. bottom quartiles = 1.19 (95% CI, 0.88–1.61)] and melanoma [pooled multivariable HR for top versus bottom quartiles = 1.31 (95% CI, 0.76–2.26)]. The associations between toenail Cr levels and SCC risk was similar to those of BCC in women [Table 5; top vs. bottom quartiles HR = 1.41 (95% CI, 0.92–2.15)]. However, toenail Cr levels were not associated with melanoma risk in either women or men. Other elements were not associated with risks of SCC and melanoma in both women and men.

Table 5.

HR and 95% CI of SCC according to toenail element exposure among women in the NHS and men in the HPFS

Quartiles of toenail element concentrationa
MetalCohortQ1Q2Q3Q4Ptrend
Mercury Women (NHS)      
 No. events 36 36 49 62  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.63–1.58) 1.35 (0.88–2.08) 1.77 (1.17–2.67) 0.001 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.91 (0.57–1.45) 1.22 (0.79–1.89) 1.57 (1.03–2.39) 0.007 
 Men (HPFS)      
 No. events 34 37 41 39  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.05 (0.66–1.68) 1.18 (0.75–1.87) 1.13 (0.71–1.80) 0.61 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.70–1.81) 1.24 (0.78–1.98) 1.24 (0.76–2.00) 0.43 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.01 (0.72–1.41) 1.23 (0.89–1.69) 1.41 (1.03–1.94) 0.04 
Selenium Women (NHS)      
 No. events 43 47 53 40  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.02 (0.67–1.55) 1.18 (0.79–1.76) 0.88 (0.57–1.36) 0.66 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.68–1.57) 1.18 (0.79–1.78) 0.82 (0.53–1.28) 0.44 
 Men (HPFS)      
 No. events (sample size) 32 34 48 37  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.61–1.62) 1.32 (0.84–2.07) 0.99 (0.61–1.59) 0.96 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.09 (0.66–1.78) 1.38 (0.87–2.19) 1.02 (0.61–1.69) 0.93 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.06 (0.77–1.45) 1.27 (0.93–1.72) 0.90 (0.65–1.26) 0.69 
Chromium Women (NHS)      
 No. events 37 42 49 55  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.72–1.74) 1.26 (0.82–1.93) 1.42 (0.93–2.16) 0.10 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.71–1.75) 1.26 (0.82–1.94) 1.41 (0.92–2.15) 0.11 
 Men (HPFS)      
 No. events 39 39 38 35  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.93 (0.59–1.46) 0.99 (0.63–1.56) 0.87 (0.55–1.38) 0.60 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.59–1.47) 1.05 (0.66–1.65) 0.95 (0.59–1.54) 0.92 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.02 (0.74–1.41) 1.15 (0.84–1.58) 1.19 (0.86–1.63) 0.26 
Iron Women (NHS)      
 No. events 53 51 38 41  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.96 (0.66–1.42) 0.71 (0.47–1.08) 0.78 (0.51–1.17) 0.18 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.96 (0.65–1.42) 0.69 (0.45–1.05) 0.79 (0.52–1.19) 0.20 
 Men (HPFS)      
 No. events 35 41 38 37  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.16 (0.74–1.84) 1.14 (0.72–1.82) 1.15 (0.72–1.83) 0.69 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.18 (0.74–1.87) 1.16 (0.72–1.87) 1.25 (0.76–2.03) 0.47 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.05 (0.78–1.41) 0.86 (0.63–1.18) 0.95 (0.69–1.31) 0.82 
Zinc Women (NHS)      
 No. events 50 50 46 37  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.67–1.47) 0.94 (0.63–1.40) 0.78 (0.51–1.20) 0.25 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.10 (0.74–1.64) 0.98 (0.65–1.47) 0.87 (0.57–1.34) 0.47 
 Men (HPFS)      
 No. events 40 43 30 38  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.13 (0.73–1.75) 0.82 (0.51–1.32) 1.04 (0.67–1.63) 0.89 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.67–1.64) 0.80 (0.46–1.39) 1.01 (0.55–1.84) 0.97 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.08 (0.80–1.45) 0.91 (0.66–1.26) 0.92 (0.65–1.30) 0.60 
Quartiles of toenail element concentrationa
MetalCohortQ1Q2Q3Q4Ptrend
Mercury Women (NHS)      
 No. events 36 36 49 62  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.63–1.58) 1.35 (0.88–2.08) 1.77 (1.17–2.67) 0.001 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.91 (0.57–1.45) 1.22 (0.79–1.89) 1.57 (1.03–2.39) 0.007 
 Men (HPFS)      
 No. events 34 37 41 39  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.05 (0.66–1.68) 1.18 (0.75–1.87) 1.13 (0.71–1.80) 0.61 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.70–1.81) 1.24 (0.78–1.98) 1.24 (0.76–2.00) 0.43 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.01 (0.72–1.41) 1.23 (0.89–1.69) 1.41 (1.03–1.94) 0.04 
Selenium Women (NHS)      
 No. events 43 47 53 40  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.02 (0.67–1.55) 1.18 (0.79–1.76) 0.88 (0.57–1.36) 0.66 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.68–1.57) 1.18 (0.79–1.78) 0.82 (0.53–1.28) 0.44 
 Men (HPFS)      
 No. events (sample size) 32 34 48 37  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.61–1.62) 1.32 (0.84–2.07) 0.99 (0.61–1.59) 0.96 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.09 (0.66–1.78) 1.38 (0.87–2.19) 1.02 (0.61–1.69) 0.93 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.06 (0.77–1.45) 1.27 (0.93–1.72) 0.90 (0.65–1.26) 0.69 
Chromium Women (NHS)      
 No. events 37 42 49 55  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.72–1.74) 1.26 (0.82–1.93) 1.42 (0.93–2.16) 0.10 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.71–1.75) 1.26 (0.82–1.94) 1.41 (0.92–2.15) 0.11 
 Men (HPFS)      
 No. events 39 39 38 35  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.93 (0.59–1.46) 0.99 (0.63–1.56) 0.87 (0.55–1.38) 0.60 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.59–1.47) 1.05 (0.66–1.65) 0.95 (0.59–1.54) 0.92 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.02 (0.74–1.41) 1.15 (0.84–1.58) 1.19 (0.86–1.63) 0.26 
Iron Women (NHS)      
 No. events 53 51 38 41  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.96 (0.66–1.42) 0.71 (0.47–1.08) 0.78 (0.51–1.17) 0.18 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.96 (0.65–1.42) 0.69 (0.45–1.05) 0.79 (0.52–1.19) 0.20 
 Men (HPFS)      
 No. events 35 41 38 37  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.16 (0.74–1.84) 1.14 (0.72–1.82) 1.15 (0.72–1.83) 0.69 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.18 (0.74–1.87) 1.16 (0.72–1.87) 1.25 (0.76–2.03) 0.47 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.05 (0.78–1.41) 0.86 (0.63–1.18) 0.95 (0.69–1.31) 0.82 
Zinc Women (NHS)      
 No. events 50 50 46 37  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.99 (0.67–1.47) 0.94 (0.63–1.40) 0.78 (0.51–1.20) 0.25 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.10 (0.74–1.64) 0.98 (0.65–1.47) 0.87 (0.57–1.34) 0.47 
 Men (HPFS)      
 No. events 40 43 30 38  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.13 (0.73–1.75) 0.82 (0.51–1.32) 1.04 (0.67–1.63) 0.89 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.04 (0.67–1.64) 0.80 (0.46–1.39) 1.01 (0.55–1.84) 0.97 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.08 (0.80–1.45) 0.91 (0.66–1.26) 0.92 (0.65–1.30) 0.60 

aMultivariable model was adjusted for assay batch, age (in years), number of severe sunburns (0, 1–2, 3–5, ≥6), number of moles (0, 1–2, 3–5, ≥6), hair color (red, blonde, light brown, dark brown, or black), family history of melanoma (yes, no), history of BCC or melanoma (yes, no), UV exposure at residence (quintiles), history of physical examination (yes, no), and sun reactions (none, burn, painful burn/blisters) in HPFS and Fitzpatrick score (I–VI) in NHS.

Table 6.

HR and 95% CI of melanoma according to toenail element exposure among women in the NHS and men in the HPFS

Quartiles of toenail element concentrationa
ElementCohortQ1Q2Q3Q4Ptrend
Mercury Women (NHS)      
 No. events 13 18 17  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.37 (0.58–3.21) 2.03 (0.91–4.52) 1.93 (0.86–4.33) 0.12 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.42 (0.60–3.34) 2.00 (0.89–4.48) 1.82 (0.80–4.14) 0.19 
 Men (HPFS)      
 No. events 15 16 18 24  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.13 (0.56–2.30) 1.16 (0.58–2.31) 1.66 (0.87–3.18) 0.09 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.17 (0.57–2.42) 1.24 (0.61–2.50) 1.92 (0.98–3.77) 0.04 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.27 (0.73–2.21) 1.52 (0.89–2.59) 1.88 (1.12–3.16) 0.02 
Selenium Women (NHS)      
 No. events 12 17 19  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.33 (0.63–2.79) 0.74 (0.31–1.77) 1.53 (0.74–3.15) 0.38 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.32 (0.62–2.80) 0.72 (0.30–1.72) 1.59 (0.76–3.35) 0.33 
 Men (HPFS)      
 No. events 16 18 20 19  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.03 (0.52–2.02) 1.07 (0.55–2.07) 1.08 (0.55–2.10) 0.82 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.14 (0.58–2.27) 1.19 (0.61–2.34) 1.15 (0.56–2.34) 0.75 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.22 (0.74–2.03) 0.99 (0.58–1.68) 1.34 (0.80–2.24) 0.43 
Chromium Women (NHS)      
 No. events 15 20 13  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.61 (0.27–1.39) 1.29 (0.66–2.52) 0.83 (0.39–1.76) 0.90 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.58 (0.25–1.34) 1.29 (0.65–2.55) 0.85 (0.40–1.81) 0.98 
 Men (HPFS)      
 No. events 12 16 25 20  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.27 (0.60–2.70) 2.03 (1.02–4.06) 1.66 (0.81–3.42) 0.23 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.39 (0.65–2.98) 2.25 (1.11–4.57) 1.89 (0.90–3.98) 0.15 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.53–1.65) 1.69 (1.03–2.76) 1.28 (0.75–2.17) 0.27 
Iron Women (NHS)      
 No. events 14 20 16  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.52 (0.21–1.28) 1.47 (0.74–2.92) 1.19 (0.58–2.44) 0.29 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.52 (0.21–1.30) 1.40 (0.70–2.79) 1.24 (0.60–2.56) 0.24 
 Men (HPFS)      
 No. events 18 20 17 18  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.59–2.13) 0.98 (0.50–1.90) 1.07 (0.56–2.07) 0.93 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.17 (0.61–2.25) 0.99 (0.49–1.98) 1.26 (0.63–2.53) 0.58 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.89 (0.52–1.51) 1.18 (0.72–1.92) 1.25 (0.75–2.07) 0.26 
Zinc Women (NHS)      
 No. events 13 10 16 18  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.76 (0.33–1.74) 1.26 (0.61–2.63) 1.49 (0.73–3.05) 0.15 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.78 (0.34–1.79) 1.33 (0.64–2.80) 1.53 (0.74–3.14) 0.14 
 Men (HPFS)      
 No. events 22 24 12 15  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.07 (0.59–1.91) 0.57 (0.28–1.15) 0.74 (0.38–1.44) 0.19 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.95 (0.52–1.74) 0.50 (0.22–1.12) 0.60 (0.24–1.48) 0.20 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.88 (0.54–1.45) 0.85 (0.49–1.48) 1.06 (0.60–1.87) 0.96 
Quartiles of toenail element concentrationa
ElementCohortQ1Q2Q3Q4Ptrend
Mercury Women (NHS)      
 No. events 13 18 17  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.37 (0.58–3.21) 2.03 (0.91–4.52) 1.93 (0.86–4.33) 0.12 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.42 (0.60–3.34) 2.00 (0.89–4.48) 1.82 (0.80–4.14) 0.19 
 Men (HPFS)      
 No. events 15 16 18 24  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.13 (0.56–2.30) 1.16 (0.58–2.31) 1.66 (0.87–3.18) 0.09 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.17 (0.57–2.42) 1.24 (0.61–2.50) 1.92 (0.98–3.77) 0.04 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.27 (0.73–2.21) 1.52 (0.89–2.59) 1.88 (1.12–3.16) 0.02 
Selenium Women (NHS)      
 No. events 12 17 19  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.33 (0.63–2.79) 0.74 (0.31–1.77) 1.53 (0.74–3.15) 0.38 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.32 (0.62–2.80) 0.72 (0.30–1.72) 1.59 (0.76–3.35) 0.33 
 Men (HPFS)      
 No. events 16 18 20 19  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.03 (0.52–2.02) 1.07 (0.55–2.07) 1.08 (0.55–2.10) 0.82 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.14 (0.58–2.27) 1.19 (0.61–2.34) 1.15 (0.56–2.34) 0.75 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.22 (0.74–2.03) 0.99 (0.58–1.68) 1.34 (0.80–2.24) 0.43 
Chromium Women (NHS)      
 No. events 15 20 13  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.61 (0.27–1.39) 1.29 (0.66–2.52) 0.83 (0.39–1.76) 0.90 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.58 (0.25–1.34) 1.29 (0.65–2.55) 0.85 (0.40–1.81) 0.98 
 Men (HPFS)      
 No. events 12 16 25 20  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.27 (0.60–2.70) 2.03 (1.02–4.06) 1.66 (0.81–3.42) 0.23 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.39 (0.65–2.98) 2.25 (1.11–4.57) 1.89 (0.90–3.98) 0.15 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.94 (0.53–1.65) 1.69 (1.03–2.76) 1.28 (0.75–2.17) 0.27 
Iron Women (NHS)      
 No. events 14 20 16  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.52 (0.21–1.28) 1.47 (0.74–2.92) 1.19 (0.58–2.44) 0.29 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.52 (0.21–1.30) 1.40 (0.70–2.79) 1.24 (0.60–2.56) 0.24 
 Men (HPFS)      
 No. events 18 20 17 18  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.12 (0.59–2.13) 0.98 (0.50–1.90) 1.07 (0.56–2.07) 0.93 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 1.17 (0.61–2.25) 0.99 (0.49–1.98) 1.26 (0.63–2.53) 0.58 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.89 (0.52–1.51) 1.18 (0.72–1.92) 1.25 (0.75–2.07) 0.26 
Zinc Women (NHS)      
 No. events 13 10 16 18  
 Age-adjusted HR (95% CI) 1.00 (reference) 0.76 (0.33–1.74) 1.26 (0.61–2.63) 1.49 (0.73–3.05) 0.15 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.78 (0.34–1.79) 1.33 (0.64–2.80) 1.53 (0.74–3.14) 0.14 
 Men (HPFS)      
 No. events 22 24 12 15  
 Age-adjusted HR (95% CI) 1.00 (reference) 1.07 (0.59–1.91) 0.57 (0.28–1.15) 0.74 (0.38–1.44) 0.19 
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.95 (0.52–1.74) 0.50 (0.22–1.12) 0.60 (0.24–1.48) 0.20 
 Women and men pooled      
 Multivariable-adjusted HR (95% CI) 1.00 (reference) 0.88 (0.54–1.45) 0.85 (0.49–1.48) 1.06 (0.60–1.87) 0.96 

aMultivariable model was adjusted for assay batch, age (in years), number of severe sunburns (0, 1–2, 3–5, ≥6), number of moles (0, 1–2, 3–5, ≥6), hair color (red, blonde, light brown, dark brown, or black), family history of melanoma (yes, no), history of BCC or SCC (yes, no), UV exposure at residence (quintiles), history of physical examination (yes, no), and sun reactions (none, burn, painful burn/blisters) in HPFS and Fitzpatrick score (I–VI) in NHS.

In this prospective study of toenail trace elements and skin cancer, we found a positive association between toenail Hg levels and risk of BCC. The association was consistent in women and men. We also found direct associations for SCC and melanoma, with limited statistical power. Other metals, except Cr in women, were not associated with skin cancer risk.

Hg, specifically as its organometallic species methylmercury, is a well-known nephro- and neurotoxin, and teratogen that primarily affects central nervous system development (38, 40–43). However, its association with cancer risk is less understood. Non-occupational exposure to Hg is predominantly through the consumption of seafood, particularly carnivorous fish, which contain methylmercury (38, 39). Although dental amalgams, which represent elemental (metallic) Hg, have been hypothesized to elevate Hg exposure (40, 44), previous evaluation in HPFS did not find that amalgam restoration was associated with toenail Hg levels (34).

Based on the ability of Hg to bind sulfhydryl groups, some have posited various molecular mechanisms for genotoxicity including generation of free radicals and oxidative stress, influence on DNA-repair mechanisms, inhibition of mitotic spindle formation, and direct interaction with DNA molecules (40, 45). Methylmercury chloride promoted renal tumors in animal studies (38, 46, 47). Human studies investigated methylmercury exposure and risk of cancer in Minamata, Japan, a site of methylmercury intoxication, and found increased mortalities due to liver cancer and leukemia (48–50). In a few small case–control studies conducted in Sweden on use of seed disinfection with organic Hg compounds, no associations were found with risk of soft-tissue sarcomas or lymphomas (51–54). Studies among mercury miners and chloralkali workers who were potentially exposed to inorganic Hg compounds have suggested potential increased risk of brain, renal, and lung cancers (38, 55–58). As such, the IARC classified methylmercury as a “potential” human carcinogen (group 2B), but metallic Hg and inorganic Hg compounds as not classifiable (group 3; ref. 38).

To our knowledge, our study was the first epidemiologic study of directly measured Hg exposure and risk of skin cancer (38). Some studies indirectly assessed Hg through possible occupational exposure and risk of melanoma. For example, dentists are exposed to Hg through dental amalgams. Three studies in Canada, Scandinavia, and Europe found that compared with the general population, dentists were at higher risk of melanoma with relative risks (RR) ranging 1.46–2.11 (59). A cohort study in Swedish women found that dental nurses were at higher risk of melanoma [RR = 1.71 (95% CI, 1.21–2.42)] than the whole population (19). That study also reported elevated melanoma risk among female hat makers [RR = 2.62 (95% CI, 1.41–4.88)] and described that mercuric nitrate was used in the production of felt hats. However, one US study found no association between dentists and melanoma risk (RR = 0.87; ref. 60).

Cr in its hexavalent state (VI) causes cancer of the lung and has been associated with cancer of the nose and nasal sinuses based on IARC (14). We are aware of only one epidemiologic study of Cr and skin cancer. A population-based case–control study in Italy examined toenail trace elements levels in 58 melanoma cases and 58 controls and found no association with toenail Cr levels (61). We found that increased toenail Cr levels were associated with BCC risk only among women independent of other metals including Hg. We do not have any biological explanations for the gender difference. There was no report of gender difference between Cr and other cancer sites in the IARC report (14). Given the paucity of data on Cr and skin cancer, further studies are needed to confirm our findings.

We found no association between Fe, Se, and Zn and risk of skin cancer for women or men. Although there are no epidemiologic studies on Fe exposure and skin cancer, Fe plays a key role in catalyzing redox reactions, which, in the presence of UVA radiation, can produce reactive oxygen species and play a role in UVA-mediated skin cell damage (62). There have been some epidemiologic studies of Se exposure using dietary, blood, and toenail levels of Se as well as supplemental Se and skin cancer (22). Some studies suggested a possible positive association between Se and SCC, but no association with risk of BCC or melanoma (21). A meta-analysis evaluating selenium supplementation and cancer risk found nonsignificant positive associations between selenium and NMSC with 4 studies [RR = 1.23 (95% CI, 0.73–2.08); ref. 21]. However, we found no association between toenail Se levels and any of the skin cancers. The epidemiologic studies on Zn and risk of skin cancer are limited, with case–control studies, and results that range from inverse to positive associations (22). Our findings using prospective data do not support any link between Zn exposure and skin cancer.

The prospective design, large number of BCC cases, evaluation in two independent cohorts, and ability to adjust for many skin cancer risk factors all represent major strengths of our study. Although we were limited by a single assessment of Hg exposure, toenail concentrations provide an excellent biomarker of integrated annual exposure. The reasonable correlation between concentrations in nails collected 6 years apart indicates that a single measurement represents exposure over longer periods (30). The findings were generally similar in two separate cohorts. However, these cohorts comprised of largely Caucasian and educated adults, potentially limiting generalizability of our findings. Still, the Hg levels were comparable to those from national data (27). We had limited sample size for SCC and, especially, melanoma, though similar directions of associations for metals and these skin cancers were found with BCC. SCC and melanoma cases were pathologically confirmed. BCC cases were documented by self-report, which could lead to a higher chance of misclassification compared with SCC or melanoma. Although we controlled for several risk factors of skin cancer, we cannot exclude residual confounding by those factors or other unknown factors. For example, we were unable to account for As exposure, which is a known NMSC carcinogen (13). However, in a small subset with toenail As levels (n = 202 NHS; n = 233 HPFS participants), the correlation between toenail Hg and As levels was low [Spearman r = 0.08 in NHS (P = 0.28) and 0.19 in HPFS (P = 0.005)]. The correlation between toenail Cr and As levels was similarly low. Therefore, although we cannot rule out the potential confounding by As exposure, it is likely to be minimal. Despite dentists comprising a large proportion of HPFS, we included a small number of dentists because we used existing data sets with toenail values that largely excluded dentists. Future evaluation of Hg levels and skin cancer risk among dentists would be of interest due to occupational Hg exposure (27).

In conclusion, our prospective data suggest that exposure to Hg, and potentially Cr, may increase skin cancer risk. Our results on toenail Hg levels and skin cancer risk were consistent by gender, type of skin cancer, and several skin cancer risk factors. Our findings need to be replicated in other populations and further investigated in terms of relevant biological mechanisms.

No potential conflicts of interest were disclosed.

All human studies have been performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and reviewed and approved by an appropriate ethics committee.

Conception and design: N.H. Matthews, T. Li, A.A. Qureshi, E. Cho

Development of methodology: N.H. Matthews, T. Li, W.C. Willett, J.S. Morris, E. Cho

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W.-Q. Li, W.C. Willett, M.J. Stampfer, J.S. Morris

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Koh, W.-Q. Li, T. Li, D.C. Christiani, J.S. Morris

Writing, review, and/or revision of the manuscript: N.H. Matthews, M. Koh, W.-Q. Li, W.C. Willett, M.J. Stampfer, D.C. Christiani, J.S. Morris, A.A. Qureshi, E. Cho

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Koh, A.A. Qureshi

Study supervision: N.H. Matthews, A.A. Qureshi, E. Cho

We would like to thank the participants and staff of the Nurses' Health Study and Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. This work was supported by the NIH (CA186107, CA167552, and CA198216) and by the Research Career Development Award of Dermatology Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Rubin
AI
,
Chen
EH
,
Ratner
D
. 
Basal-cell carcinoma
.
N Engl J Med
2005
;
353
:
2262
9
.
2.
Marzuka
AG
,
Book
SE
. 
Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management
.
Yale J Biol Med
2015
;
88
:
167
79
.
3.
Alam
M
,
Ratner
D
. 
Cutaneous squamous-cell carcinoma
.
N Engl J Med
2001
;
344
:
975
83
.
4.
Matthews
NH
,
Li
WQ
,
Qureshi
AA
,
Weinstock
MA
,
Cho
E
. 
Epidemiology of melanoma
.
In:
Ward
WH
,
Farma
JM
,
editors
.
Cutaneous Melanoma: etiology and therapy
.
Brisbane, Australia
:
Codon Publications
; 
2017
.
5.
Rogers
HW
,
Weinstock
MA
,
Feldman
SR
,
Coldiron
BM
. 
Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012
.
JAMA Dermatol
2015
;
151
:
1081
6
.
6.
Boyd
AS
,
Shyr
Y
,
King
LE
 Jr
. 
Basal cell carcinoma in young women: an evaluation of the association of tanning bed use and smoking
.
J Am Acad Dermatol
2002
;
46
:
706
9
.
7.
Guy
GP
,
Ekwueme
DU
. 
Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature
.
Pharmacoeconomics
2011
;
29
:
863
74
.
8.
Guy
GP
 Jr
,
Machlin
SR
,
Ekwueme
DU
,
Yabroff
KR
. 
Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011
.
Am J Prev Med
2015
;
48
:
183
7
.
9.
Gallagher
RP
,
Hill
GB
,
Bajdik
CD
,
Fincham
S
,
Coldman
AJ
,
McLean
DI
, et al
Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma
.
Arch Dermatol
1995
;
131
:
157
63
.
10.
Martens
MC
,
Seebode
C
,
Lehmann
J
,
Emmert
S
. 
Photocarcinogenesis and skin cancer prevention strategies: an update
.
Anticancer Res
2018
;
38
:
1153
8
.
11.
Wu
S
,
Han
J
,
Li
WQ
,
Li
T
,
Qureshi
AA
. 
Basal-cell carcinoma incidence and associated risk factors in U.S. women and men
.
Am J Epidemiol
2013
;
178
:
890
7
.
12.
Savas
S
,
Turgut Erdemir
AV
,
Koku Aksu
AE
,
Gurel
MS
,
Ozkur
E
. 
Clinical and prognostic factors in the development of basal cell carcinoma
.
Clin Dermatol
2017
;
35
:
616
23
.
13.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
. 
Arsenic, metals, fibres, and dusts
.
IARC Monogr Eval Carcinog Risks Hum
2012
;
100
:
11
465
.
14.
Chromium, nickel and welding
.
IARC Monogr Eval Carcinog Risks Hum
1990
;
49
:
1
648
.
15.
Davidson
T
,
Kluz
T
,
Burns
F
,
Rossman
T
,
Zhang
Q
,
Uddin
A
, et al
Exposure to chromium (VI) in the drinking water increases susceptibility to UV-induced skin tumors in hairless mice
.
Toxicol Appl Pharmacol
2004
;
196
:
431
7
.
16.
Uddin
AN
,
Burns
FJ
,
Rossman
TG
,
Chen
H
,
Kluz
T
,
Costa
M
. 
Dietary chromium and nickel enhance UV-carcinogenesis in skin of hairless mice
.
Toxicol Appl Pharmacol
2007
;
221
:
329
38
.
17.
Weinberg
ED
. 
The role of iron in cancer
.
Eur J Cancer Prev
1996
;
5
:
19
36
.
18.
Gorodetsky
R
,
Sheskin
J
,
Weinreb
A
. 
Iron, copper, and zinc concentrations in normal skin and in various nonmalignant and malignant lesions
.
Int J Dermatol
1986
;
25
:
440
5
.
19.
Perez-Gomez
B
,
Aragones
N
,
Gustavsson
P
,
Plato
N
,
Lopez-Abente
G
,
Pollan
M
. 
Cutaneous melanoma in Swedish women: occupational risks by anatomic site
.
Am J Ind Med
2005
;
48
:
270
81
.
20.
Magnani
C
,
Coggon
D
,
Osmond
C
,
Acheson
ED
. 
Occupation and five cancers: a case-control study using death certificates
.
Br J Ind Med
1987
;
44
:
769
76
.
21.
Vinceti
M
,
Filippini
T
,
Del Giovane
C
,
Dennert
G
,
Zwahlen
M
,
Brinkman
M
, et al
Selenium for preventing cancer
.
Cochrane Database Syst Rev
2018
;
1
:
Cd005195
.
22.
Matthews
NH
,
Fitch
K
,
Li
WQ
,
Morris
JS
,
Christiani
DC
,
Qureshi
AA
, et al
Exposure to trace elements and risk of skin cancer: a systematic review of epidemiologic studies
.
Cancer Epidemiol Biomarkers Prev
2019
;
28
:
3
21
.
23.
Li
WQ
,
Cho
E
,
Weinstock
MA
,
Mashfiq
H
,
Qureshi
AA
. 
Epidemiological assessments of skin outcomes in the Nurses' Health Studies
.
Am J Public Health
2016
;
106
:
1677
83
.
24.
Park
MK
,
Li
WQ
,
Qureshi
AA
,
Cho
E
. 
Fat intake and risk of skin cancer in U.S. adults
.
Cancer Epidemiol Biomarkers Prev
2018
;
27
:
776
82
.
25.
Mozaffarian
D
,
Shi
P
,
Morris
JS
,
Grandjean
P
,
Siscovick
DS
,
Spiegelman
D
, et al
Methylmercury exposure and incident diabetes in U.S. men and women in two prospective cohorts
.
Diabetes Care
2013
;
36
:
3578
84
.
26.
Mozaffarian
D
,
Shi
P
,
Morris
JS
,
Grandjean
P
,
Siscovick
DS
,
Spiegelman
D
, et al
Mercury exposure and risk of hypertension in US men and women in 2 prospective cohorts
.
Hypertension
2012
;
60
:
645
52
.
27.
Mozaffarian
D
,
Shi
P
,
Morris
JS
,
Spiegelman
D
,
Grandjean
P
,
Siscovick
DS
, et al
Mercury exposure and risk of cardiovascular disease in two U.S. cohorts
.
N Engl J Med
2011
;
364
:
1116
25
.
28.
Rajpathak
S
,
Rimm
EB
,
Li
T
,
Morris
JS
,
Stampfer
MJ
,
Willett
WC
, et al
Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men
.
Diabetes Care
2004
;
27
:
2211
6
.
29.
National Analysis Center for Iron & Steel
.
NCS Reference Material (2016–2017)
.
In:
NCS Testing Technology Co., Ltd.,
editor
.
Beijing, China
. 
2016
.
p.
81
.
30.
Garland
M
,
Morris
JS
,
Rosner
BA
,
Stampfer
MJ
,
Spate
VL
,
Baskett
CJ
, et al
Toenail trace element levels as biomarkers: reproducibility over a 6-year period
.
Cancer Epidemiol Biomarkers Prev
1993
;
2
:
493
7
.
31.
Longnecker
MP
,
Stram
DO
,
Taylor
PR
,
Levander
OA
,
Howe
M
,
Veillon
C
, et al
Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake
.
Epidemiology
1996
;
7
:
384
90
.
32.
Longnecker
MP
,
Stampfer
MJ
,
Morris
JS
,
Spate
V
,
Baskett
C
,
Mason
M
, et al
A 1-y trial of the effect of high-selenium bread on selenium concentrations in blood and toenails
.
Am J Clin Nutr
1993
;
57
:
408
13
.
33.
Park
K
,
Rimm
E
,
Siscovick
D
,
Spiegelman
D
,
Morris
JS
,
Mozaffarian
D
. 
Demographic and lifestyle factors and selenium levels in men and women in the U.S
.
Nutr Res Pract
2011
;
5
:
357
64
.
34.
Joshi
A
,
Douglass
CW
,
Kim
HD
,
Joshipura
KJ
,
Park
MC
,
Rimm
EB
, et al
The relationship between amalgam restorations and mercury levels in male dentists and nondental health professionals
.
J Public Health Dent
2003
;
63
:
52
60
.
35.
MacIntosh
DL
,
Williams
PL
,
Hunter
DJ
,
Sampson
LA
,
Morris
SC
,
Willett
WC
, et al
Evaluation of a food frequency questionnaire-food composition approach for estimating dietary intake of inorganic arsenic and methylmercury
.
Cancer Epidemiol Biomarkers Prev
1997
;
6
:
1043
50
.
36.
van Dam
RM
,
Huang
Z
,
Giovannucci
E
,
Rimm
EB
,
Hunter
DJ
,
Colditz
GA
, et al
Diet and basal cell carcinoma of the skin in a prospective cohort of men
.
Am J Clin Nutr
2000
;
71
:
135
41
.
37.
Colditz
GA
,
Martin
P
,
Stampfer
MJ
,
Willett
WC
,
Sampson
L
,
Rosner
B
, et al
Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women
.
Am J Epidemiol
1986
;
123
:
894
900
.
38.
International Agency for Research on Cancer
. 
Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. Working Group views and expert opinions, Lyon, 9–16 February 1993
.
IARC Monogr Eval Carcinog Risks Hum
1993
;
58
:
1
415
.
39.
Holmes
P
,
James
KA
,
Levy
LS
. 
Is low-level environmental mercury exposure of concern to human health?
Sci Total Environ
2009
;
408
:
171
82
.
40.
Crespo-Lopez
ME
,
Macedo
GL
,
Pereira
SI
,
Arrifano
GP
,
Picanco-Diniz
DL
,
do Nascimento
JL
, et al
Mercury and human genotoxicity: critical considerations and possible molecular mechanisms
.
Pharmacol Res
2009
;
60
:
212
20
.
41.
Young
HA
,
Geier
DA
,
Geier
MR
. 
Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink
.
J Neurol Sci
2008
;
271
:
110
8
.
42.
Tchounwou
PB
,
Ayensu
WK
,
Ninashvili
N
,
Sutton
D
. 
Environmental exposure to mercury and its toxicopathologic implications for public health
.
Environ Toxicol
2003
;
18
:
149
75
.
43.
Counter
SA
,
Buchanan
LH
. 
Mercury exposure in children: a review
.
Toxicol Appl Pharmacol
2004
;
198
:
209
30
.
44.
Kingman
A
,
Albertini
T
,
Brown
LJ
. 
Mercury concentrations in urine and whole blood associated with amalgam exposure in a US military population
.
J Dent Res
1998
;
77
:
461
71
.
45.
Koedrith
P
,
Kim
H
,
Weon
JI
,
Seo
YR
. 
Toxicogenomic approaches for understanding molecular mechanisms of heavy metal mutagenicity and carcinogenicity
.
Int J Hyg Environ Health
2013
;
216
:
587
98
.
46.
Mitsumori
K
,
Hirano
M
,
Ueda
H
,
Maita
K
,
Shirasu
Y
. 
Chronic toxicity and carcinogenicity of methylmercury chloride in B6C3F1 mice
.
Fundam Appl Toxicol
1990
;
14
:
179
90
.
47.
Hirano
M
,
Mitsumori
K
,
Maita
K
,
Shirasu
Y
. 
Further carcinogenicity study on methylmercury chloride in ICR mice
.
Nihon Juigaku Zasshi
1986
;
48
:
127
35
.
48.
Tamashiro
H
,
Akagi
H
,
Arakaki
M
,
Futatsuka
M
,
Roht
LH
. 
Causes of death in Minamata disease: analysis of death certificates
.
Int Arch Occup Environ Health
1984
;
54
:
135
46
.
49.
Tamashiro
H
,
Arakaki
M
,
Futatsuka
M
,
Lee
ES
. 
Methylmercury exposure and mortality in southern Japan: a close look at causes of death
.
J Epidemiol Community Health
1986
;
40
:
181
5
.
50.
Kinjo
Y
,
Akiba
S
,
Yamaguchi
N
,
Mizuno
S
,
Watanabe
S
,
Wakamiya
J
, et al
Cancer mortality in Minamata disease patients exposed to methylmercury through fish diet
.
J Epidemiol
1996
;
6
:
134
8
.
51.
Eriksson
M
,
Hardell
L
,
Adami
HO
. 
Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study
.
J Natl Cancer Inst
1990
;
82
:
486
90
.
52.
Eriksson
M
,
Hardell
L
,
Berg
NO
,
Moller
T
,
Axelson
O
. 
Soft-tissue sarcomas and exposure to chemical substances: a case-referent study
.
Br J Ind Med
1981
;
38
:
27
33
.
53.
Hardell
L
,
Eriksson
M
. 
The association between soft tissue sarcomas and exposure to phenoxyacetic acids. A new case-referent study
.
Cancer
1988
;
62
:
652
6
.
54.
Hardell
L
,
Eriksson
M
,
Lenner
P
,
Lundgren
E
. 
Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: a case-control study
.
Br J Cancer
1981
;
43
:
169
76
.
55.
Boffetta
P
,
Garcia-Gomez
M
,
Pompe-Kirn
V
,
Zaridze
D
,
Bellander
T
,
Bulbulyan
M
, et al
Cancer occurrence among European mercury miners
.
Cancer Causes Control
1998
;
9
:
591
9
.
56.
Zadnik
V
,
Pompe-Kirn
V
. 
Effects of 500-year mercury mining and milling on cancer incidence in the region of Idrija, Slovenia
.
Coll Antropol
2007
;
31
:
897
903
.
57.
Barregard
L
,
Sallsten
G
,
Jarvholm
B
. 
Mortality and cancer incidence in chloralkali workers exposed to inorganic mercury
.
Br J Ind Med
1990
;
47
:
99
104
.
58.
Ellingsen
DG
,
Andersen
A
,
Nordhagen
HP
,
Efskind
J
,
Kjuus
H
. 
Incidence of cancer and mortality among workers exposed to mercury vapour in the Norwegian chloralkali industry
.
Br J Ind Med
1993
;
50
:
875
80
.
59.
Fortes
C
,
de Vries
E
. 
Nonsolar occupational risk factors for cutaneous melanoma
.
Int J Dermatol
2008
;
47
:
319
28
.
60.
Pion
IA
,
Rigel
DS
,
Garfinkel
L
,
Silverman
MK
,
Kopf
AW
. 
Occupation and the risk of malignant melanoma
.
Cancer
1995
;
75
(
2 Suppl
):
637
44
.
61.
Vinceti
M
,
Bassissi
S
,
Malagoli
C
,
Pellacani
G
,
Alber
D
,
Bergomi
M
, et al
Environmental exposure to trace elements and risk of cutaneous melanoma
.
J Expo Anal Environ Epidemiol
2005
;
15
:
458
62
.
62.
Vile
GF
,
Tyrrell
RM
. 
UVA radiation-induced oxidative damage to lipids and proteins in vitro and in human skin fibroblasts is dependent on iron and singlet oxygen
.
Free Radic Biol Med
1995
;
18
:
721
30
.